NL-OMON31643已完成3 期
A Phase 3 Clinical Trial to evaluate the safety and efficacy of treatment with 2 mg intralesional Allovectin-7® compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in subjects with recurrent metastatic melanoma - Allovectin-7® immunotherapy for metastatic melanoma (A.I.M.M.)
Vical Incorporated0 个研究点目标入组 15 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Histologically confirmed recurrent metastatic melanoma, which may have received primary surgical resection, adjuvant therapy, and/or biotherapy
- •* At least one injectable lesion (cutaneous, subcutaneous, or nodal lesion) *1 cm2 and * 25 cm2
- •* Normal LDH
- •* ECOG performance status of 0 or 1
排除标准
- •* Surgery is deemed a curative option
- •* Prior cytotoxic chemotherapy
- •* Any lesion *100 cm2
- •* History of visceral metastasis, M1c, other than lung (M1b not excluded)
研究者
相似试验
进行中（未招募）
不适用
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7® Immunotherapy for Metastatic Melanoma (A.I.M.M)Recurrent metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-004120-21-BEVical Incorporated375
进行中（未招募）
不适用
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7® Immunotherapy for Metastatic Melanoma (A.I.M.M)EUCTR2007-004120-21-NLVical Incorporated375
进行中（未招募）
不适用
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7® Immunotherapy for Metastatic Melanoma (A.I.M.M)EUCTR2007-004120-21-PLVical Incorporated375
进行中（未招募）
不适用
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7® Immunotherapy for Metastatic Melanoma (A.I.M.M)EUCTR2007-004120-21-DEVical Incorporated375
进行中（未招募）
1 期
A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids - Study of Zoster vaccine in subjects on chronic steroid maintenanceZoster VaccineMedDRA version: 8.1 Level: LLT Classification code 10019974 Term: Herpes zosterEUCTR2006-003651-20-GBMerck & Co Inc.,300